Hypericum perforatum methanolic extract inhibits growth of human prostatic carcinoma cell line orthotopically implanted in nude mice

Cancer Letters

Volumn 210, Issue 1, 2004, Pages 27-33

  Martarelli, D ^a   Martarelli, B ^b   Pediconi, D ^a   Nabissi, M I ^c   Perfumi, M ^a   Pompei, P ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b Dept Morphological Sci Compar B ^*  (Italy)

^c Synbiotec Srl   (Italy)

Author keywords

Hypericum perforatum; Neuroendocrine differentiation; Prostate cancer; Serotonin

Indexed keywords

ANTINEOPLASTIC AGENT; HYPERICUM PERFORATUM EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HYPERICUM PERFORATUM; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; HUMANS; HYPERICUM; MALE; METHANOL; MICE; MICE, NUDE; PLANT EXTRACTS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

HYPERICUM; HYPERICUM PERFORATUM; MUS MUSCULUS;

EID: 2542465858     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.01.031     Document Type: Article

References (48)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J. Clin. (49):1999;8-31
2. Kyprianou N., English H.F., Isaacs J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 50:1990;3748-3753
3. Tenniswood M.P., Guenette R.S., Lakins J., Mooibroek M., Wong P., Welsh J.E. Active cell death in hormone-dependent tissues. Cancer Metastasis Rev. 11:1992;197-220
4. Abrahamsson P.A. Neuroendocrine cells in tumour growth of the prostate. Endocr. Relat. Cancer. 6:1999;503-519
5. di Sant'Agnese P.A. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer. 70:1992;254-268
6. Abdul M., Logothetis C.J., Hoosein N.M. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J. Urol. 154:1995;247-250
7. Abdul M., Anezinis P.E., Logothetis C.J., Hoosein N.M. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res. 14:1994;1215-1220
8. Schulz V. Clinical trials with hypericum extracts in patients with depression-results, comparisons, conclusions for therapy with antidepressant drugs. Phytomedicine. 9:2002;468-474
9. Behnke K., Jensen G.S., Graubaum H.J., Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv. Ther. 19:2002;43-52
10. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int. Clin. Psychopharmacol. 15:2000;61-68
11. Anonimo, Scheda tecnica: Prozac, Repertorio Farmaceutico Italiano. Farmindustria/Cedof Editore, Milano 2002.
12. Muller W.E., Rolli M., Schafer C., Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 30:1997;102-107
13. Neary J.T., Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res. 816:1999;358-363
14. Perovic S., Muller W.E. Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung. 45:1995;1145-1148
15. Cott J.M. In vivo receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry. 30:1997;108-112
16. Nahrstedt A., Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry. 30:1997;129-134
17. Bennett D.A. Jr., Phun L., Polk J.F., Voglino S.A., Zlotnik V., Raffa R.B. Neuropharmacology of St. John's Wort (Hypericum). Ann Pharmacother. 32:1998;1201-1208
18. Calapai G., Crupi A., Firenzuoli F., Costantino G., Inferrera G., Campo G.M., Caputi A.P. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. J. Pharm. Pharmacol. 51:1999;723-728
19. Kaehler S.T., Sinner C., Chatterjee S.S., Philippu A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Neurosci. Lett. 262:1999;199-202
20. Muller W.E., Singer A., Wonnemann M., Hafner U., Rolli M., Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry. 31:1998;16-21
21. Singer A., Wonnemann M., Muller W.E. Hyperforin, a major antidepressant constituent of St John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J. Pharmacol. Exp. Ther. 290:1999;1363-1368
22. Hostanska K., Reichling J., Bommer S., Weber M., Saller R. Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur. J. Pharm. Biopharm. 56:2003;121-132
23. Hostanska K., Reichling J., Bommer S., Weber M., Saller R. Aqueous ethanolic extract of StJohn's wort (Hypericum perforatum L.) induces growth inhibition and apoptosis in human malignant cells in vitro. Pharmazie. 57:2002;323-331
24. Schempp C.M., Kirkin V., Simon-Haarhaus B., Kersten A., Kiss J., Termeer C.C., et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St John's wort that acts by induction of apoptosis. Oncogene. 21:2002;1242-1250
25. Xie X., Hudson J.B., Guns E.S. Tumor-specific and photodependent cytotoxicity of hypericin in the human LNCaP prostate tumor model. Photochem. Photobiol. 74:2001;221-225
26. Begun F.P. Lepor H., Lawson R.K. Epidemiology and Natural History of Prostate Cancer in Prostate Diseases. 1993;Saunders
27. Beynon L.L., Busuttil A., Newsam J.E., Chisholm G.D. Incidental carcinoma of the prostate: selection for deferred treatment. Br. J. Urol. 55:1983;733-736
28. Tanagho E.A., McAninch J.W. Smith's General Urology. 1995;Appleton e Lange
29. Hoosein N.M., Bandyk M.G., Nicolson G.L., Logothesis C.J., Chung L.W.K. Espression of neuroendocrine markers and extracellular matrix degradative enzymes in human prostate cells. J. Urol. 149:1993;1066. 479A#1066
30. Bonkhoff H., Stein U., Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum. Pathol. 26:1995;167-170
31. Krijnen J.L., Janssen P.J., Ruizeveld de Winter J.A., van Krimpen H., Schroder F.H., van der Kwast T.H. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry. 100:1993;393-398
32. Bonkhoff H., Wernert N., Dhom G., Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate. 19:1991;91-98
33. Grobholz R., Bohrer M.H., Siegsmund M., Junemann K.P., Bleyl U., Woenckhaus M. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol. Res. Pract. 196:2000;277-284
34. Whitaker-Azmitia P.M., Peroutka S.J. The Neuropharmacology of Serotonin. Ann. N.Y. Acad. Sci. 600:1990;1-715
35. Seuwen K., Pouyssegur J. Serotonin as a growth factor. Biochem. Pharmacol. 39:1990;985-990
36. Nemecek G.M., Coughlin S.R., Handley D.A., Moskowitz M.A. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc. Natl. Acad. Sci. USA. 83:1986;674-678
37. Takuwa N., Ganz M., Takuwa Y., Sterzel R.B., Rasmussen H. Studies of the mitogenic effect of serotonin in rat renal mesangial cells. Am. J. Physiol. 257:1989;431-439
38. Tutton P.J., Barkla D.H. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells. Anticancer Res. 7:1987;1-12
39. Nair H.K., Rao K.V., Aalinkeel R., Mahajan S., Chawda R., Schwartz S.A. Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin. Diagn. Lab Immunol. 11:2004;63-69
40. Bleiker E.M., Ploeg H.M. Psychosocial factors in the etiology of breast cancer: review of a popular link. Patient Edu. Couns. 37:1999;201-214
41. Carney C.P., Jones L., Woolson R.F., Noyes R. Jr., Doebbeling B.N. Relationship between depression and pancreatic cancer in the general population. Psychosom. Med. 65:2003;884-888
42. Spiegel D., Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol. Psychiatry. 54:2003;269-282
43. von Bahr C., Ursing C., Yasui N., Tybring G., Bertilsson L., Rojdmark S. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur. J. Clin. Pharmacol. 56:2000;123-127
44. Hartter S., Wang X., Weigmann H., Friedberg T., Arand M., Oesch F., Hiemke C. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J. Clin. Psychopharmacol. 21:2001;167-174
45. Shiu S.Y., Law I.C., Lau K.W., Tam P.C., Yip A.W., Ng W.T. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J. Pineal. Res. 35:2003;177-182
46. Siu S.W., Lau K.W., Tam P.C., Shiu S.Y. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate. 52:2002;106-122
47. Marelli M.M., Limonta P., Maggi R., Motta M., Moretti R.M. Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate. 45:2000;238-244
48. Harrer G., Schulz V. Clinical investigation of the antidepressant effectiveness of hypericum. J. Geriatr. Psichiatry Neurol. 7:1994;S6-S8